Browse by Poster Presenter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

X
Xia, Angela

International Flavors and Fragrances Inc.
(M1230-02-09) Comparison of Controlled-Release Performance between Carrageenan and Several Other Hydrophilic Polymers
Angela Xia
Favorite
(T1130-11-70) Application of Colloidal MCC and Xanthan in Challenging Suspension Formulation
Angela Xia
Favorite
Xia, Li

US Food and Drug Administration
(M1430-12-83) Common Deficiencies Using Alternative Bioequivalence Approach for Metered Dose Inhaler in Abbreviated New Drug Applications
Li Xia
Favorite
(W0930-03-20) In Vitro Evaluation of Two Morphine Sulfate Extended-Release Products Sprinkled on Soft Foods
Li Xia
Favorite
Xiang, Tianyi

University of Minnesota
(M0930-08-55) Worsened Punch Sticking by External Lubrication with Magnesium Stearate
Tianyi Xiang
Favorite
Xiao, Jieyu

WuXi AppTec (Shanghai) Co., Ltd.
(W1030-05-33) Study on the Permeability of Ophthalmic Tissues In Vitro
Jieyu Xiao
Favorite
Xia, P.

Colorcon, Inc.
(W0930-02-11) Influence of Coating Parameters on Uniformity and Yield of Immediate Release Coating Formulation of a Low Dose Drug (Linagliptin) onto Metformin HCl ER Tablets - Fixed Dose Combination
P. Xia
Favorite
Xia, Wenxi

University of Utah
(M1230-10-68) Ultrasmall Nanoprobes for Fluorescence-Guided Surgical Resection of Peritoneally Disseminated Tumors
Wenxi Xia
Favorite
Xia, Ziyun

University of Michigan
(M1530-09-58) Critical Manufacturing Parameters and Their Impacts on the Product Attributes of Bupivacaine Multivesicular Liposomal Formulation (Exparel^®)
Ziyun Xia
Favorite
Xie, Huan

Texas Southern University
(M1030-04-26) Impact of Host Physiological and Pathological Conditions on the Activity of Gut Microbial Beta-Glucuronidases (GUS) toward Hydrolysis of Flavonoids-Glucoronides
Huan Xie
Favorite
(M1230-11-71) Design and Development of Nanoformulation of GMC1, a Novel Agent for the Treatment of Castration Resistant Prostate Cancer
Huan Xie
Favorite
(T1230-02-12) Non-haemolytic Nanoemulsions Development and Characterization for Novel Anti-prostate Cancer Compound PC257
Huan Xie
Favorite
(T1430-10-68) Metabolite Identification of R14 in Rat Urine after a Single Oral Administration to Rats Using UPLC-TOF MS/MS
Huan Xie
Favorite
(W1030-01-03) The Design and Assessment of Sustained Release from PLGA/PEG Blend Nanoparticles for Intravenous Application
Huan Xie
Favorite
Xie, Jiashu

University of Minnesota
(T1530-05-29) Discovery of a Deazaflavin Analog as Potent and Selective Inhibitor of Multidrug Resistance-Associated Protein 1 (MRP1)
Jiashu Xie
Favorite
Xie, Tongzhen

University of Minnesota
(T1530-05-33) Characterizing the Pharmacological Mechanism of Agmatine in the Spinal Cord Using Calcium Imaging and NMDA-induced Behavioral Assays
Tongzhen Xie
Favorite
Xie, Yuling

Vertex Pharmaceuticals, Inc.
(T1030-09-62) Interconversion Kinetic Study to Assess Class II Atropisomeric Drug Development Challenges
Yuling Xie
Favorite
Xie, Zhiliang

Ohio State University
(M1530-05-29) The Effect of Cancer-Associated Cachexia on the Pharmacokinetics of Extra-vascularly Administered Monoclonal Antibodies
Zhiliang Xie
Favorite
Xi, Hanmi

Merck & Co., Inc.
(M1430-09-57) Using Enzymes to Accelerate PS80 Degradation and Elucidate Mechanistic Impacts of PS80 Degradants on Protein Stability via Thermal- and Agitation-Induced Aggregation
Hanmi Xi
Favorite
Xing, Lili

WuXi AppTec (Shanghai) Co., Ltd.
(M0930-06-41) Comparison of Branched DNA (B-DNA) and Polymerase Chain Reaction (RT-qPCR) Method Validation for the Quantification of mRNA Therapeutics in Plasma
Lili Xing
Favorite
(M1330-06-40) A Comprehensive Bioanalytical Strategy of In Vivo Studies for RNAi Therapeutics in Early Discovery
Lili Xing
Favorite
(T0930-06-38) Quantitative Analysis of GalNAc-siRNA Conjugates in Tissue Homogenate Using Two-Dimensional Liquid Chromatography Coupled with Tandem Mass Spectrometry
Lili Xing
Favorite
(T1430-06-41) Research Strategy of Chiral PROTACs in Discovery Stage Based on Analysis Platforms of UPCC-MS/MS and UPLC-MS/MS
Lili Xing
Favorite
Xin, Lun

Catalent Pharma Solutions
(M1130-12-77) Stabilization and Formulation Development of Lipid Nanoparticles (LNPs) for Nucleic Acid-Based Therapeutics
Lun Xin
Favorite
Xin, Xiaofei

University of Nebraska Medical Center
(M1030-02-08) A Novel Liposomal Delivery for MicroRNA-497 and Venetoclax in Acute Myeloid Leukemia
Xiaofei Xin
Favorite
Xiong, Feng

International Flavors and Fragrances Inc.
(M1230-02-09) Comparison of Controlled-Release Performance between Carrageenan and Several Other Hydrophilic Polymers
Feng Xiong
Favorite
(T1130-11-70) Application of Colloidal MCC and Xanthan in Challenging Suspension Formulation
Feng Xiong
Favorite
(T1230-02-08) Application of Ac-Di-Sol® SD-711 in Orally Disintegrating Tables (ODTs): Performance Comparison of Croscarmellose Sodium and Crospovidone
Feng Xiong
Favorite
Xiong, Shunbin

MD Anderson Cancer Institute
(T1230-04-22) The Paracrine Action of Mutant p53 in Breast Cancer
Shunbin Xiong
Favorite
Xi, Yuecheng

Boehringer Ingelheim
(W1030-06-39) Comprehensive LC-MS/MS Analysis of VSV-GP Lipidome
Yuecheng Xi
Favorite
Xu, Bibo

Primera Analytical Solutions Corp.
(M0930-06-40) Increased Throughput for Regulated Bioanalysis with Catch-and-Hold Mode of HPLC Separation with High Sensitivity Mass Spectrometers
Bibo Xu
Favorite
(M1430-08-50) Leachable Analysis of Ethylene Vinyl Acetate Infusion Bags by GC-FID-MS and LC-UV-MS
Bibo Xu
Favorite
(T1430-08-50) Analytical Case Studies for Processed-Induced and API-Related Nitrosamines in Finished Drug Products
Bibo Xu
Favorite
Xu, Bin

Accurant Biotech
(W1030-06-36) Novel Technical Breakthrough: qPCR with Reported LLOQ of 8 Copies / mg DNA in a 20 µL Reaction
Bin Xu
Favorite
Xu, Chao

University of Oklahoma Health Sciences Center
(M1230-05-33) Concurrent Regulation of OATP1B1 Transport Function by Protein Phosphorylation and Acetylation: Novel Mechanism Underlying Reduced Function of OATP1B1 c.521T >C Single Nucleotide Polymorphism
Chao Xu
Favorite
(T1230-05-32) Regulation of OATP1B3 Transport Function via Protein Acetylation
Chao Xu
Favorite
Xu, Cheng

University of Michigan
(M1130-05-31) Antigen-Specific Tolerogenic Nanodiscs for the Treatment of Experimental Autoimmune Encephalomyelitis
Cheng Xu
Favorite
Xu, Cong

Drug Farm
(T1230-10-69) Metabolite Identification of Nucleoside Analog Prodrugs in Biological Matrix by Derivatization Coupled with Radio-Detector and Mass Spectrometry
Cong Xu
Favorite
Xu, Donghong

Cytokinetics, Incorporated
(M1430-10-69) Disposition and Metabolism of the Cardiac Myosin Inhibitor Aficamten in Humans
Donghong Xu
Favorite
(W1130-10-69) Pharmacokinetics, Excretion, and Metabolism of [¹⁴C]Aficamten Following Single Oral Dose Administration to Rats
Donghong Xu
Favorite
Xue, Liang

University of the Pacific
(M1530-02-13) Preparation of Nanoparticles Based on Krafft Point of Nonionic Polyoxyethylated Amphiphiles
Liang Xue
Favorite
Xu, Haiyue

University of Texas at Austin
(M1430-03-15) Development of 3D Printable Inks for Protein Delivery
Haiyue Xu
Favorite
(W0930-03-15) Oral Delivery of Probiotics Using Delayed-Release Capsules: Formulation and Dosage Form Considerations
Haiyue Xu
Favorite
Xu, Jenny

Merck & Co., Inc.
(M1130-09-56) Development of an Industry Ready Cell-Based Potency Method for an Oncolytic Virus Immunotherapy
Jenny Xu
Favorite
Xu, Jianchao

Purdue University
(M1330-12-83) Physical Stability of Amorphous Pharmaceutical Formulations Insights into Crystallization Behavior
Jianchao Xu
Favorite
Xu, Jin

University of Michigan
(M1130-05-31) Antigen-Specific Tolerogenic Nanodiscs for the Treatment of Experimental Autoimmune Encephalomyelitis
Jin Xu
Favorite
Xu, Qingguo

Virginia Commonwealth University
(T1330-11-74) Novel LAAM Immediate Release Capsule for Treating Opioid Use Disorder
Qingguo Xu
Favorite
Xu, Qun

United States Pharmacopeia
(M1230-09-56) Trace Level Quantification of Nitrosamine Impurities in Tuberculosis Medicines by LC-MS/MS
Qun Xu
Favorite
Xu, Shiqing

Texas A&M University
(M1330-02-11) Formulation and Characterization of Non-invasive Nebulization Based Antiviral Drug, NSF207 Loaded Pegylated Nanoliposomal Suspension Product for Treatment of COVID-19
Shiqing Xu
Favorite
Xu, Xiaoming

US Food and Drug Administration
(M1330-08-55) Understanding Release Mechanism and Development of Accelerated Release Tests for Long-Term Intrauterine Systems
Xiaoming Xu
Favorite
(M1530-09-58) Critical Manufacturing Parameters and Their Impacts on the Product Attributes of Bupivacaine Multivesicular Liposomal Formulation (Exparel^®)
Xiaoming Xu
Favorite
(T1230-08-55) Long-Term Stability of In-House Sunscreen Formulations
Xiaoming Xu
Favorite
(T1330-08-49) Continuous Processing of Liposomal Nanoparticles as Potential Reference Materials for Drug Product Development
Xiaoming Xu
Favorite
(T1530-09-61) Effect of Collagen Source on the In Vitro Performance of Collagen Implant
Xiaoming Xu
Favorite
(T1530-12-78) Preclinical Evaluation of Brinzolamide Ophthalmic Suspensions with Variations in Critical Quality Attributes and Considerations for Pharmacokinetic/Pharmacodynamic Study Designs
Xiaoming Xu
Favorite
(W0930-08-52) Method Development for the Evaluation of Orally Inhaled Drug Products (OIDPs) containing Spray-Dried Phospholipid Porous Particles (PPPs)
Xiaoming Xu
Favorite
Xu, Xiaoyan

University College London
(T1130-02-13) Rapid Production of Personalized Medicines Using Tomographic Volumetric 3D Printing
Xiaoyan Xu
Favorite
(W0930-08-55) Distributed Manufacturing of 3D Printed Pharmaceuticals: A Case Study
Xiaoyan Xu
Favorite
Xu, Xin

National Institutes of Health
(T1030-10-68) Machine Learning-Based Prediction of Aldehyde Oxidase Activity in Multiple Species
Xin Xu
Favorite
(T1430-06-40) Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method Development and Pharmacokinetics of PTH-IA in Mice
Xin Xu
Favorite
Xu, Yunming

US Food and Drug Administration
(M1430-10-64) Physiologically Based Biopharmaceutics Modeling of BCS Class I Extended-Release Drug Products: A Preliminary Exploration
Yunming Xu
Favorite
Xu, Zhen

US Food and Drug Administration
(M1430-12-83) Common Deficiencies Using Alternative Bioequivalence Approach for Metered Dose Inhaler in Abbreviated New Drug Applications
Zhen Xu
Favorite
Xu, Zizhao

University of the Pacific
(T1130-04-23) The Response of an Orthotopic Lung Cancer Xenograft Model to Cisplatin
Zizhao Xu
Favorite